Michael Yeaman: Building Optimism in the Field of Neuromyelitis Optica

Video

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

Unlike conditions like multiple sclerosis where there is a considerable amount of knowledge and several available approved treatment options that is not the case for neuromyelitis optica. As a result more work is needed to educate patients about what their treatment will be like.

As a Medical Advisor to the Guthy Jackson Charitable Foundation, Michael R. Yeaman, PhD, has seen the work of the foundation make a big impact in moving the treatment of NMO forward in just a few short years. While it may be a few years before treatments are approved for the treatment of NMO, Yeaman said that is still a brighter picture than patients and their providers had just a few short years ago.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.